Form 4: Passage Bio Director Acquires Stock Options

Director Thomas Richard Kassberg acquired stock options in Passage Bio, Inc. on September 30, 2024.

Summary

• On September 30, 2024, Thomas Richard Kassberg, a director of Passage Bio, Inc., acquired employee stock options.
• The options grant the right to buy 174,139 shares of common stock at an exercise price of $0.70.
• The options vest monthly, starting October 10, 2024, over a period of 36 months, contingent on continued service to the company.
• The options expire on September 30, 2034.
• Following the transaction, Kassberg directly owns 174,139 derivative securities.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing. The sentiment is neutral, reflecting standard corporate governance practices.

Positives

• The acquisition of stock options by a director signals confidence in the company's future prospects.
• The vesting schedule incentivizes the director to remain with the company and contribute to its success.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates a change in the beneficial ownership of securities by a company insider.

Stakeholder Impact

• The acquisition of stock options by a director could positively influence shareholder sentiment.

Key Dates